Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings DaShenLin Pharmaceutical Group Co., Ltd.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: DaShenLin Pharmaceutical Group Co., Ltd.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: DaShenLin Pharmaceutical Group Co., Ltd.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • The group usually releases earnings worse than estimated.

Rating Financials

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.09B
BB
15.05B
AA
5.91B
AAA
3.9B
AAA
3.22B
BBB
2.96B
AAA
2.63B - - - - -
2.56B -
BBB
- -
1.51B
AAA
-
1.51B
AA
Average 4.23B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 603233 Stock
  4. Ratings DaShenLin Pharmaceutical Group Co., Ltd.